Phase 4 N=87 Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes
Diabetes Mellitus
Primary: Time in Range — 10.9; 11.5; 13.3; 12.3 hours per day — p=0.9345
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=94 Effectiveness and Safety of the Levitan Scope for Laryngoscopy and Tracheal Intubation With a Simulated Difficult Airway
Airway Complication of Anaesthesia
Primary: Cormack-Lehane Grade — 58; 53; 33; 41 participants
Phase 4 N=44 Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia
Insomnia
Primary: Mean Change in the Insomnia Severity Index — -4.01; 0.72 units on a scale
Phase 4 N=17 Effect of Omega-3 Fatty Acid on Vitamin D Activation
Hemodialysis Patients · Vitamin D Insufficiency · Vitamin D Deficiency
Primary: 25-hydroxyvitamin D Levels at 12 Weeks — 44.4; 48.9 ng/ml
Phase 4 N=100 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
Parkinson's Disease · Essential Tremor · Dystonia
Primary: Identify the Rate of User-related Battery Depletion Adverse Events Per Subject-month Requiring Intervention by a Health Care Professional (HCP) and/or the HCP's…
Phase 4 N=51 Quartet Lead and Resynchronization Therapy Options
Heart Failure
Primary: Number of Patients Whose Cardiac Output (CO) Value in Acute, as Measured Echocardiographically, Improves With the Different Stimulation Vectors Offered by the Quartet®…
Phase 4 N=46 Massage for Pain Relief During the Active Phase of Labor
Pain
Primary: Effectiveness of Massage Therapy in Pain Relief During Labor. — 68.7; 69.0; 72.1; 51.7 milimeters
Phase 4 N=17 Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)
Flushing
Primary: Whether Quercetin Dose-dependently Reduces Laser Doppler Flux Index Primary Peak Following Immediate-release Niacin — 9.9; 9.4; 7.7; 8.9 Fold change over baseline — p=0.5
Phase 4 N=56 Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery
Pain, Postoperative
Primary: Postoperative Pain Assessed on Standard VAS Scale — 0.48; 1.12 units on a scale
Phase 4 N=39 Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient
Atelectasis
Primary: Improvement of Atelectasis — 6; 7; 3; 6 participants
Phase 4 N=48 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary Myelofibrosis (PMF) · Post Polycythaemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary: Percentage of Participants With Treatment Success — 50 Percentage of participants
Phase 4 N=180 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
End-stage Renal Disease
Primary: Chronic Allograft Nephropathy (Cumulative Calcineurin-inhibitor Nephrotoxicity/Transplant Nephropathy) Per Protocol Surveillance Kidney Biopsies (Banff Grading…
Phase 4 N=276 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
Gastroesophageal Reflux Disease
Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants
Phase 4 N=60 A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
Non-ST or ST Elevation Acute Coronary Syndromes
Primary: the Percentage Inhibition of the P2Y12 Receptor — 48.20; 9.78 Percentage Inhibition — p=0.0021
Phase 4 N=200 Assessment of the Implementation of the ResQGARD® Impedance Threshold Device by the San Antonio Fire Department
Acute Hypotension
Primary: Change in Systolic Blood Pressure From Baseline (Before ITD Use) — 17.9 mmHg